$ACAD
ACADIA PHARMACEUTICALS INC Stock $acad

$acad Overview Financials Valuation SEC Filings Company Website

2014 Q3 Form 10-Q Financial Statement

#000119312514295781 Filed on August 05, 2014

Income Statement

Concept	2014 Q3	2014 Q2	2013 Q2
Revenue	$15.00K	$28.00K	$451.0K
YoY Change	-93.75%	-93.79%	-24.71%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$8.100M	$8.000M	$2.500M
YoY Change	113.16%	220.0%	56.25%
% of Gross Profit
Research & Development	$16.95M	$13.80M	$7.112M
YoY Change	133.69%	94.02%	59.03%
% of Gross Profit
Depreciation & Amortization	$60.00K	$50.00K
YoY Change	50.0%
% of Gross Profit
Operating Expenses	$25.01M	$21.75M	$9.608M
YoY Change	126.31%	126.38%	59.39%
Operating Profit	-$24.99M	-$21.72M	-$9.157M
YoY Change	131.19%	137.23%	68.67%
Interest Expense	$208.0K	$228.0K	$76.00K
YoY Change	79.31%	200.0%	660.0%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$24.80M	-$21.50M	-$9.100M
YoY Change	131.78%	136.26%	68.52%
Income Tax			$0.00
% Of Pretax Income
Net Earnings	-$24.79M	-$21.50M	-$9.081M
YoY Change	131.75%	136.7%	67.58%
Net Earnings / Revenue	-165240.0%	-76767.86%	-2013.53%
Basic Earnings Per Share
Diluted Earnings Per Share	-$249.2K	-$205.2K	-$109.1K
COMMON SHARES
Basic Shares Outstanding	99.44M shares	98.98M shares	79.16M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2014 Q3	2014 Q2	2013 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$337.8M	$354.5M	$205.5M
YoY Change	72.19%	72.52%	864.56%
Cash & Equivalents	$36.37M	$13.70M	$24.25M
Short-Term Investments	$301.4M	$340.8M	$181.2M
Other Short-Term Assets	$2.100M	$3.100M	$1.300M
YoY Change	-16.0%	138.46%	225.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$341.1M	$358.9M	$206.8M
YoY Change	71.67%	73.56%	849.53%
LONG-TERM ASSETS
Property, Plant & Equipment	$520.0K	$500.0K	$92.00K
YoY Change	6.12%	443.48%	0.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$178.0K	$111.0K	$56.00K
YoY Change	48.33%	98.21%	700.0%
Total Long-Term Assets	$698.0K	$611.0K	$148.0K
YoY Change	14.43%	312.84%	49.49%
TOTAL ASSETS
Total Short-Term Assets	$341.1M	$358.9M	$206.8M
Total Long-Term Assets	$698.0K	$611.0K	$148.0K
Total Assets	$341.8M	$359.5M	$206.9M
YoY Change	71.49%	73.73%	845.91%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.110M	$1.104M	$1.177M
YoY Change	-0.89%	-6.2%	55.48%
Accrued Expenses	$10.13M	$8.206M	$6.488M
YoY Change	51.84%	26.48%	24.17%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$11.25M	$9.339M	$7.776M
YoY Change	42.99%	20.1%	15.03%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$0.00	$0.00	$17.70M
YoY Change	-100.0%	-100.0%	637.5%
Total Long-Term Liabilities	$21.00K	$18.00K	$17.70M
YoY Change	950.0%	-99.9%	637.5%
TOTAL LIABILITIES
Total Short-Term Liabilities	$11.25M	$9.339M	$7.776M
Total Long-Term Liabilities	$21.00K	$18.00K	$17.70M
Total Liabilities	$11.27M	$9.357M	$25.40M
YoY Change	43.22%	-63.16%	177.11%
SHAREHOLDERS EQUITY
Retained Earnings	-$469.8M	-$445.0M	-$382.9M
YoY Change	19.35%	16.21%	6.81%
Common Stock	$10.00K	$10.00K	$8.000K
YoY Change	11.11%	25.0%	60.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$330.5M	$350.1M	$181.5M
YoY Change
Total Liabilities & Shareholders Equity	$341.8M	$359.5M	$206.9M
YoY Change	71.49%	73.73%	845.91%

Cashflow Statement

Concept	2014 Q3	2014 Q2	2013 Q2
OPERATING ACTIVITIES
Net Income	-$24.79M	-$21.50M	-$9.081M
YoY Change	131.75%	136.7%	67.58%
Depreciation, Depletion And Amortization	$60.00K	$50.00K
YoY Change	50.0%
Cash From Operating Activities	-$17.48M	-$16.97M	-$5.440M
YoY Change	84.58%	211.95%	13.33%
INVESTING ACTIVITIES
Capital Expenditures	-$80.00K	$0.00	-$60.00K
YoY Change	-81.4%	-100.0%
Acquisitions
YoY Change
Other Investing Activities	$38.96M	-$67.51M	-$98.55M
YoY Change	-1206.82%	-31.5%	-1274.61%
Cash From Investing Activities	$38.87M	-$67.51M	-$98.61M
YoY Change	-1084.05%	-31.54%	-1275.33%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$107.9M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	1.280M	1.720M	109.9M
YoY Change	31.96%	-98.43%	183016.67%
NET CHANGE
Cash From Operating Activities	-17.48M	-16.97M	-5.440M
Cash From Investing Activities	38.87M	-67.51M	-98.61M
Cash From Financing Activities	1.280M	1.720M	109.9M
Net Change In Cash	22.67M	-82.76M	5.820M
YoY Change	-282.09%	-1521.99%	59.45%
FREE CASH FLOW
Cash From Operating Activities	-$17.48M	-$16.97M	-$5.440M
Capital Expenditures	-$80.00K	$0.00	-$60.00K
Free Cash Flow	-$17.40M	-$16.97M	-$5.380M
YoY Change	92.48%	215.43%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2014Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	99436825	shares
CY2013Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	24247000
CY2014Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	99300702	shares
CY2014Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2014Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2014Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2014Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2014Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2014Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2014Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	99300702	shares
CY2014Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2014Q2	us-gaap	Liabilities Current LiabilitiesCurrent	9339000
CY2014Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	94000
CY2014Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1245000
CY2014Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	187000
CY2014Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	794995000
CY2014Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	1104000
CY2014Q2	us-gaap	Stockholders Equity StockholdersEquity	350108000
CY2014Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-444991000
CY2014Q2	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	29000
CY2014Q2	us-gaap	Preferred Stock Value PreferredStockValue
CY2014Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	8206000
CY2014Q2	us-gaap	Liabilities Liabilities	9357000
CY2014Q2	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	18000
CY2014Q2	us-gaap	Common Stock Value CommonStockValue	10000
CY2014Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	359465000
CY2014Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	111000
CY2014Q2	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	340755000
CY2014Q2	us-gaap	Interest Receivable Current InterestReceivableCurrent	1320000
CY2014Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	500000
CY2014Q2	us-gaap	Assets Assets	359465000
CY2014Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	13698000
CY2014Q2	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	340665000
CY2014Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	34500000
CY2014Q2	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	340755000
CY2014Q2	us-gaap	Investments Fair Value Disclosure InvestmentsFairValueDisclosure	354310000
CY2014Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3081000
CY2014Q2	us-gaap	Assets Current AssetsCurrent	358854000
CY2014Q2	acad	Accrued Consulting And Other Professional Fees AccruedConsultingAndOtherProfessionalFees	1230000
CY2014Q2	acad	Accrued Clinical Development Services AccruedClinicalDevelopmentServices	5544000
CY2014Q2	acad	Available For Sale Securities Gross Unrealized Gain Accumulated In Investments AvailableForSaleSecuritiesGrossUnrealizedGainAccumulatedInInvestments	125000
CY2014Q2	acad	Available For Sale Securities Gross Unrealized Loss Accumulated In Investments AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments	35000
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	57899000
CY2013Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	91102618	shares
CY2013Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2013Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2013Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2013Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2013Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2013Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2013Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	91102618	shares
CY2013Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2013Q4	us-gaap	Liabilities Current LiabilitiesCurrent	6979000
CY2013Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	48000
CY2013Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1865000
CY2013Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	172000
CY2013Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	587742000
CY2013Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	372000
CY2013Q4	us-gaap	Stockholders Equity StockholdersEquity	182131000
CY2013Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-405668000
CY2013Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	55000
CY2013Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2013Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	6552000
CY2013Q4	us-gaap	Liabilities Liabilities	6987000
CY2013Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	8000
CY2013Q4	us-gaap	Common Stock Value CommonStockValue	9000
CY2013Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	189118000
CY2013Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	179000
CY2013Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	174083000
CY2013Q4	us-gaap	Interest Receivable Current InterestReceivableCurrent	750000
CY2013Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	579000
CY2013Q4	us-gaap	Assets Assets	189118000
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	11707000
CY2013Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	174038000
CY2013Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	174083000
CY2013Q4	us-gaap	Investments Fair Value Disclosure InvestmentsFairValueDisclosure	185831000
CY2013Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1820000
CY2013Q4	us-gaap	Assets Current AssetsCurrent	188360000
CY2013Q4	acad	Accrued Consulting And Other Professional Fees AccruedConsultingAndOtherProfessionalFees	308000
CY2013Q4	acad	Accrued Clinical Development Services AccruedClinicalDevelopmentServices	4207000
CY2013Q4	acad	Available For Sale Securities Gross Unrealized Gain Accumulated In Investments AvailableForSaleSecuritiesGrossUnrealizedGainAccumulatedInInvestments	59000
CY2013Q4	acad	Available For Sale Securities Gross Unrealized Loss Accumulated In Investments AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments	14000
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-12029000
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	81105000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	10854000	shares
	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	162032000
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.19
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	74000
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-30000
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	56000
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2014
	dei	Document Type DocumentType	10-Q
	dei	Document Period End Date DocumentPeriodEndDate	2014-06-30
	dei	Entity Central Index Key EntityCentralIndexKey	0001070494
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Entity Registrant Name EntityRegistrantName	ACADIA PHARMACEUTICALS INC
	dei	Amendment Flag AmendmentFlag	false
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	117000
	us-gaap	Increase Decrease In Accounts Receivable And Other Operating Assets IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets	556000
	us-gaap	Revenues Revenues	868000
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	173000
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-15234000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-15321000
	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	11000
	us-gaap	Net Income Loss NetIncomeLoss	-15204000
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-473000
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	110079000
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4647000
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-33652000
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-131702000
	us-gaap	Operating Expenses OperatingExpenses	16189000
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-323000
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	2349000
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-198000
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	110079000
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	11000
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	30393000
	us-gaap	Depreciation Depreciation	24000
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1646000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	11542000
	dei	Trading Symbol TradingSymbol	ACAD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-31149000
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	96042000	shares
	us-gaap	Description Of New Accounting Pronouncements Not Yet Adopted DescriptionOfNewAccountingPronouncementsNotYetAdopted	<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b>10. Recent Accounting Pronouncements</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> In May 2014, the Financial Accounting Standards Board issued authoritative accounting guidance related to revenue from contracts with customers<i>.</i> This guidance is a comprehensive new revenue recognition model that requires a company to recognize revenue to depict the transfer of goods or services to a customer at an amount that reflects the consideration it expects to receive in exchange for those goods or services. This guidance is effective for annual reporting periods beginning after December 15, 2016 and early adoption is not permitted. The Company will adopt this guidance on January 1, 2017. Companies may use either a full retrospective or a modified retrospective approach to adopt this guidance. The Company is evaluating which transition approach to use and its impact, if any, on its consolidated financial statements.</p> </div>
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	9595000	shares
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.41
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y9M18D
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	6000
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	46000
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-68000
	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	288639000
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	358000
	us-gaap	Increase Decrease In Accounts Receivable And Other Operating Assets IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets	570000
	us-gaap	Revenues Revenues	58000
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1261000
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-39277000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-39681000
	us-gaap	Net Income Loss NetIncomeLoss	-39323000
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	11000
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	199762000
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	14272000
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	1991000
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-166622000
	us-gaap	Operating Expenses OperatingExpenses	39739000
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-26000
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	1654000
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	732000
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	199762000
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	10000
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	122023000
	us-gaap	Depreciation Depreciation	85000
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	7493000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	25467000
	us-gaap	Other Than Temporary Impairment Losses Investments Availableforsale Securities OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities	0
CY2014Q1	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	7360000	shares
CY2013Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	10942000	shares
CY2013Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.11
CY2013Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-41000
CY2013Q2	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	76000
CY2014Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	196800000
CY2013	us-gaap	Other Than Temporary Impairment Losses Investments Availableforsale Securities OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities	0
CY2013Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	83410000	shares
CY2013Q2	us-gaap	Revenues Revenues	451000
CY2013Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-9122000
CY2013Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-9157000
CY2013Q2	us-gaap	Net Income Loss NetIncomeLoss	-9081000
CY2013Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2496000
CY2013Q2	us-gaap	Operating Expenses OperatingExpenses	9608000
CY2013Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1100000
CY2013Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	7112000
CY2014Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	99048000	shares
CY2014Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	9738000	shares
CY2014Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.22
CY2014Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	94000
CY2014Q2	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	228000
CY2014Q2	us-gaap	Revenues Revenues	28000
CY2014Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-21401000
CY2014Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-21723000
CY2014Q2	us-gaap	Net Income Loss NetIncomeLoss	-21495000
CY2014Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	7952000
CY2014Q2	us-gaap	Operating Expenses OperatingExpenses	21751000
CY2014Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4300000
CY2014Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	13799000

Files In Submission

Name	View Source	Status
0001193125-14-295781-index-headers.html	Edgar Link	pending
0001193125-14-295781-index.html	Edgar Link	pending
0001193125-14-295781.txt	Edgar Link	pending
0001193125-14-295781-xbrl.zip	Edgar Link	pending
acad-20140630.xml	Edgar Link	completed
acad-20140630.xsd	Edgar Link	pending
acad-20140630_cal.xml	Edgar Link	unprocessable
acad-20140630_def.xml	Edgar Link	unprocessable
acad-20140630_lab.xml	Edgar Link	unprocessable
acad-20140630_pre.xml	Edgar Link	unprocessable
d743030d10q.htm	Edgar Link	pending
d743030dex101.htm	Edgar Link	pending
d743030dex102.htm	Edgar Link	pending
d743030dex311.htm	Edgar Link	pending
d743030dex312.htm	Edgar Link	pending
d743030dex321.htm	Edgar Link	pending
d743030dex322.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ACAD
ACADIA PHARMACEUTICALS INC Stock $acad

2014 Q3 Form 10-Q Financial Statement

#000119312514295781 Filed on August 05, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ACAD ACADIA PHARMACEUTICALS INC Stock $acad

2014 Q3 Form 10-Q Financial Statement

#000119312514295781 Filed on August 05, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ACAD
ACADIA PHARMACEUTICALS INC Stock $acad